SEC Form 4
Keros Therapeutics, Inc. (KROS) insider trading
In the 12 months to Nov 20, 2026, 5 KROS insiders reported open-market sales of $113.5K across 8 filings; one director bought $75.8K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $113.5K
- 8 filings · 5 insiders
- Open-market purchases
- $75.8K
- 6 filings · Jean Jacques Bienaime, Director
- Pre-arranged sales (10b5-1)
- 8 of 8
- All $113.5K sold was pre-arranged
Who traded KROS, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
KROS daily close from Nov 20, 2025 to Nov 20, 2026, between $9.17 and $21.84, last $11.06. 8 sale and 6 purchase filings by 6 insiders, marked at their filing dates. Jean Jacques Bienaime, Director: bought $75.8K across 6 filings, first filed Mar 11, 2026, last Aug 19, 2026. Julius Knowles, Director: sold $28.2K across 1 filing, first filed Jun 8, 2026, last Jun 8, 2026. Nima Farzan, Director: sold $28.2K across 1 filing, first filed Jun 8, 2026, last Jun 8, 2026. Alpna Seth, Director: sold $28.1K across 1 filing, first filed Jun 5, 2026, last Jun 5, 2026. Charles W. Newton, Director: sold $17.2K across 3 filings, first filed Jun 15, 2026, last Nov 19, 2026. Anne Prener, Director: sold $11.8K across 2 filings, first filed Nov 16, 2026, last Nov 19, 2026.
Largest mark · tap a row for others
Julius Knowles · Director
Sale $28,166
2,625 shares at $10.73 avg
Filed Jun 8, 2026 · traded Jun 4
Pre-arranged (10b5-1) · close on filing date $10.00
Jean Jacques Bienaime · Director
Director
$75.8K boughtJulius Knowles · Director
Director
$28.2K soldNima Farzan · Director
Director
$28.2K soldAlpna Seth · Director
Director
$28.1K soldCharles W. Newton · Director
Director
$17.2K soldAnne Prener · Director
Director
$11.8K soldOpen-market trades
14 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Jean Jacques Bienaime | Director | — | $75.8K | 6 | — | |
| Julius Knowles | Director | $28.2K | — | 1 | 100% of sales | |
| Nima Farzan | Director | $28.2K | — | 1 | 100% of sales | |
| Alpna Seth | Director | $28.1K | — | 1 | 100% of sales | |
| Charles W. Newton | Director | $17.2K | — | 3 | 100% of sales | |
| Anne Prener | Director | $11.8K | — | 2 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Anne Prener Director | SalePre-arranged (10b5-1) | 575 | $10.83 | $6.2K | 12,779 | |
traded | Charles W. Newton Director | SalePre-arranged (10b5-1) | 551 | $10.85 | $6.0K | 11,623 | |
traded | Anne Prener Director | SalePre-arranged (10b5-1) | 574 | $9.79 | $5.6K | 13,212 | |
traded | Charles W. Newton Director | SalePre-arranged (10b5-1) | 551 | $10.30 | $5.7K | 12,114 | |
traded | Jean Jacques Bienaime Director | PurchasePre-arranged (10b5-1) | 1,000 | $10.27 | $10.3K | 19,592 | |
traded | Jean Jacques Bienaime Director | PurchasePre-arranged (10b5-1) | 1,000 | $10.61 | $10.6K | 18,592 | |
traded | Jean Jacques Bienaime Director | PurchasePre-arranged (10b5-1) | 1,000 | $10.19 | $10.2K | 17,592 | |
traded | Charles W. Newton Director | SalePre-arranged (10b5-1) | 550 | $10.04 | $5.5K | 12,665 | |
traded | Nima Farzan Director | SalePre-arranged (10b5-1) | 2,625 | $10.73 | $28.2K | 9,767 | |
traded | Julius Knowles Director | SalePre-arranged (10b5-1) | 2,625 | $10.73 | $28.2K | 10,958 | |
traded | Alpna Seth Director | SalePre-arranged (10b5-1) | 2,625 | $10.72 | $28.1K | 9,767 | |
traded | Jean Jacques Bienaime Director | PurchasePre-arranged (10b5-1) | 1,000 | $10.58 | $10.6K | 9,450 | |
traded | Jean Jacques Bienaime Director | PurchasePre-arranged (10b5-1) | 1,000 | $11.70 | $11.7K | 8,450 | |
traded | Jean Jacques Bienaime Director | PurchasePre-arranged (10b5-1) | 2,000 | $11.21 | $22.4K | 7,450 |
GET /stocks/filings/vX/form-4?tickers=KROS&filing_date.gte=2025-11-20&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"KROS"
],
"issuer_cik": "0001664710",
"owner_cik": "0001797917",
"accession_number": "0001797917-26-000011",
"form_type": "4",
"filing_date": "2026-11-19",
"period_of_report": "2026-11-17",
"issuer_name": "Keros Therapeutics, Inc.",
"issuer_trading_symbol": "KROS",
"owner_name": "Prener Anne",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-11-17",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 142,
"transaction_price_per_share": 11.03,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 12637,
"transaction_value": 1566.26,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 6, 2026."
},
{
"id": "F3",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.03 to $11.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
}
]
},
{
"tickers": [
"KROS"
],
"issuer_cik": "0001664710",
"owner_cik": "0001866219",
"accession_number": "0001866219-26-000012",
"form_type": "4",
"filing_date": "2026-11-19",
"period_of_report": "2026-11-17",
"issuer_name": "Keros Therapeutics, Inc.",
"issuer_trading_symbol": "KROS",
"owner_name": "Newton Charles W.",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-11-17",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 60,
"transaction_price_per_share": 11.05,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 11563,
"transaction_value": 663,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026."
},
{
"id": "F3",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.04 to $11.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 21 records
- Option exercises1 record
- Tax withholding (sold to cover)7 records
- Grants and awards7 records
- Other6 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Keros Therapeutics, Inc.'s CEO sold stock?
No. Jasbir Seehra (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is KROS’s insider data?
These are KROS Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track KROS insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for KROS every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.